Other reported adverse reactions occurring in greater than or equal to 2% of patients treated with REL/IPM/CS were headache, increased alanine aminotransferase, increased aspartate aminotransferase, pyrexia, and hypertension [27]. This evidence concerns the gene GPT and Hypertension.